Semma Therapeutics

Acquired by Vertex
Developing cell therapies for treating type 1 diabetes.

F-Prime Team

Sector

Life Sciences

Category

Therapeutics

Location

Cambridge, MA

Initial Investment

2014
Developing cell therapies for treating type 1 diabetes.

Semma Therapeutics is a regenerative medicine company founded to develop transformative stem cell-derived therapies to provide a functional cure for patients with diabetes. This company was acquired by Vertex in 2019.

“F-Prime played a crucial role in Semma's groundbreaking approach, supporting a new therapeutic modality with the potential for a functional cure for T1D. Thier focus on outcomes and patients, rather than profit, made all the difference.”
Doug Melton, Cofounder & CEO